THERE has been growing interest in understanding whether perioperative events such as short-term exposure to a general anesthesia could have a deleterious effect on the oncologic outcomes of cancer surgery by promoting growth and progression of the so-called minimally residual disease. Specifically, it has been hypothesized that the use of volatile anesthetics could be associated with minimally residual disease proliferation, whereas propofol could promote apoptosis and have antimetastatic effects.1 In this issue of Anesthesiology, Makito et al.2 report the results of a retrospective study evaluating the association between overall or recurrence-free survival after cancer surgery and the use of propofol-based total intravenous anesthesia versus volatile anesthetic-based general anesthesia. This cohort study included cancer patients who underwent esophagectomy, gastrectomy, hepatectomy, cholecystectomy, pancreatectomy, colectomy, and rectal cancer surgery.2 Makito et al. have to be commended...
Anesthetic Drugs and Cancer Progression: Fact or Fiction
This editorial accompanies the article on p. 764.
Accepted for publication July 15, 2020. Published online first on August 17, 2020.
- Views Icon Views
- Share Icon Share
- Search Site
Juan P. Cata, Anil K. Sood, Holger K. Eltzschig; Anesthetic Drugs and Cancer Progression: Fact or Fiction. Anesthesiology 2020; 133:698–699 doi: https://doi.org/10.1097/ALN.0000000000003510
Download citation file: